UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/776,450	02/11/2004	Wesley K.M. Chong	PC19074	3704

28940 7590 05/16/2005

AGOURON PHARMACEUTICALS, INC.
10350 NORTH TORREY PINES ROAD
LA JOLLA, CA 92037

EXAMINER	
LEE, SUSANNAH E	

ART UNIT	PAPER NUMBER
1626	

DATE MAILED: 05/16/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/776,450	CHONG ET AL.	
	Examiner	Art Unit	
	Susannah Lee	1626	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *04 April 2005*.

2a)☒ This action is **FINAL**. 2b)☐ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) *1-9* is/are pending in the application.

4a) Of the above claim(s) *7-9* is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☒ Claim(s) *1-6* is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☒ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date *11/22/04*.
4) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____ .
5) ☐ Notice of Informal Patent Application (PTO-152)
6) ☐ Other: _____.

S.L.J.

DETAILED ACTION

Claims 1-9 are pending in the instant application. Claims 7-9 are withdrawn by Applicant.

Priority

This application claims benefit of provisional application number 60/447,329, filed on 02/12/2003.

Response to Non-Final Office Action

Amendment of Claims

Acknowledgment is made of applicant's amendment of the claims filed on 04/04/2005.

Confirmation of Election/Restriction

Applicant's confirmation of the election of Group I, Claims 1-8, without traverse is acknowledged.

Examiner's 35 USC 103 Rejection

Applicant disagrees with Examiner's 35 USC 103 rejection because "Applicants submit that the Examiner has failed to point to any motivation or suggestion in the prior art to replace the carbonyl with the elaborated sulfonyl and sulfonamide groups of the present invention." (Applicant's Remarks, page 154, lines 30-32).

Examiner respectfully disagrees with Applicant and will maintain the rejection of Claims 1-6 under 35 U.S.C. 103(a) because the Chong reference does provide the requisite motivation to make the instantly elected/claimed compounds (see analysis below). This rejection is set forth in a prior Office Action, mailed on 11/29/2004.

Examiner's 35 USC 112 Rejection

Examiner's 35 USC 112 rejection is withdrawn in light of the amendment to the claims filed on 04/04/2005, where Applicant deletes "prodrug or pharmaceutically active metabolite of a compound of

the Formula (I) or pharmaceutically acceptable salt." (see Amendments to the Claims, filed on 04/04/2005, pages 4, 6, 8, 10, and 12).

Scope of the Elected Invention

Claims 1-9 are pending in this application. The scope of the invention of the elected subject matter is as follows:

Compounds of formula, (II)  , depicted in claim 2, wherein: R_4 is C2-C14 alkyl, C3-C10cycloalkyl, or aryl, R_5 is hydroxyl, halo, C1-C14 alkyl, C1-C14 alkoxyl, acyl, $R_{5'}$ and $R_{5''}$ are hydrogen, hydroxyl, halo, C1-14 alkyl, C1-14 alkoxyl, acyl, R_6 is  , R_7 is hydrogen, hydroxyl, halo, C1-C14 alkyl, C1-14 alkoxyl, acyl; and $R_{9'}$ is hydrogen, C1-C9 alkyl, C2-C9 alkenyl, 2-9 membered heteroalkenyl, C1C9 alkylamide, C1-C9 alkyl-carboxamide, C1-C4 alkyl-cycloalkyl, C1-C4 alkyl-aryl, C3-C10 cycloalkyl, and aryl.

Scope of Withdrawn Subject Matter

Claims 1-6 (in part) and 7-9 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention.

As a result of the election, Claims 1-6 (in part) are withdrawn from further consideration pursuant to 37 CRF 1.142(b) as being drawn to non-elected inventions. The withdrawn compounds contain varying core structures, such as pyrimidinyl, piperidinyl, imidazolyl, pyrrolidinyl, etc., which are chemically recognized to differ in structure and function. This recognized chemical diversity of the functional groups can be seen by the various classifications of these functional groups in the U.S. Classification System. For instance, thiazoles are in various subclasses of class 548 and the heteroaryl moieties are in various subclasses of classes 544 (pyrimidines), 546 (pyridines), 548 (indoles), and 549

(thiophenes). Therefore the subject matter which are withdrawn from consideration as being non-elected subject matter differ materially in structure and composition and have been restricted properly.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

> (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* **v.** *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 1-6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Chong et al., U.S. Pat. No. 6,569,878.

Applicants instant elected invention teaches the compound of formula,



(m) , depicted in claim 5 and their multimers, wherein: R_4 is phenyl, R_5 is H, $R_{5'}$ and $R_{5''}$ are F, R_6 is  , R_7 is hydrogen; and $R_{9'}$ is C1-C9 alkyl, 2-9 membered heteroalkenylC1-C4 alkyl-heteroaryl, and 3-10 membered heteroaryl, yielding the compounds depicted in claim 5, page 10, line 2 and 9,  and  .

These products, according to claims 8 and 9, page 13, lines 5-9, can be used for treating cellular proliferative diseases, cancer, autoimmune disease, viral disease, fungal disease, neurodegenerative disorder or cardiovascular disease.

Determination of the scope and content of the prior art (MPEP § 2141.01)

Chong teaches diamino substituted thiazole compounds and the pharmaceutically acceptable salts thereof depicted by the formula,  or {4-Amino-2-[4-(4-methyl-piperazine-1-sulfonyl)-phenylamino]-thiazol-5-yl}-(2,6-difluoro-phenyl)-methanone, (See Pat. No. 6,569,878, Columns 95 and 193, Example C(116));



or 4-[4-Amino-5-(2,6-difluoro-benzoyl)-thiazol-2-ylamino]-N-piperidin-4-ylmethyl-benzenesulfonamide, (See Pat. No. 6,569,878, Columns 124 and 193, Example J(4)). These products can be used to alleviate the symptoms of cellular proliferative diseases and cancer (Column 3, lines 29-43).

Ascertainment of the difference between the prior art and the claims (MPEP § 2141.02)

The difference between the prior art of Chong and the instantly claimed compounds is a methyl versus hydrogen group. There are two species that are claimed in the instant application that are taught in Chong. In the first example, Chong teaches a 4-methyl-piperazine group off the sulfonyl group, while the instant application discloses a piperazine group. The difference being a hydrogen instead of a methyl at the 4 position of the piperazine ring in the instant application. In the second example, Chong teaches a piperidine group off the sulfonyl group, while the instant application discloses 2-methyl-piperidine. The difference being a methyl instead of a hydrogen at the 2 position of the piperidine ring in the instant application.

Finding of prima facie obviousness – rationale and motivation (MPEP § 2142-2413)

However, in the absence of showing unobvious results, it would have been obvious to one of ordinary skill in the art at the time of the invention when faced with Chong et al. to make products that are useful for the treatment of cellular proliferative diseases and cancer, wherein methyl and hydrogen are interchangeable.

In the first example noted above, Chong teaches a tertiary amine and the instant application discloses a secondary amine. This is an obvious variant. The interchange of alkyl and hydrogen is

obvious in and of itself. Secondary and tertiary amines are interchangeable. Ex parte Bluestone, 135 USPQ 199.

In the second example, Chong teaches a hydrogen substituent off the piperidine ring, while the instant application discloses a methyl substituent. Hydrogen and methyl are deemed obvious variants. In re Wood, 199 USPQ 137.

The motivation would be to prepare similar compounds pharmacologically active against cellular proliferative diseases and cancer. Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention when faced with Chong et al. to make products that are useful for the treatment of cellular proliferative diseases and cancer, wherein methyl and hydrogen are interchangeable.

Obviousness Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington,* 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-6 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over Claims 1-14 of U.S. Patent Num. 6,569,878 (`878 Patent).

Applicants instant elected invention teaches the compound of formula,



(II) , depicted in claim 5 and their multimers, wherein: R_4 is phenyl, R_5 is H, $R_{5'}$ and $R_{5''}$ are F, R_6 is  , R_7 is hydrogen; and $R_{9'}$ is C1-C9 alkyl, 2-9 membered heteroalkenylC1-C4 alkyl-heteroaryl, and 3-10 membered heteroaryl, yielding the compounds depicted in claim 5, page 10, line 2 and 9,  and  . These products, according to claims 8 and 9, page 13, lines 5-9, can be used for treating cellular proliferative diseases, cancer, autoimmune disease, viral disease, fungal disease, neurodegenerative disorder or cardiovascular disease.

Determination of the scope and content of the prior art (MPEP § 2141.01)

`878 Patent teaches diamino substituted thiazole compounds and the pharmaceutically acceptable salts thereof depicted by the formula,



or {4-Amino-2-[4-(4-methyl-piperazine-1-sulfonyl)-phenylamino]-thiazol-5-yl}-(2,6-difluoro-phenyl)-methanone, (See Pat. No. 6,569,878, Columns 95 and 193, Example C(116));



or 4-[4-Amino-5-(2,6-difluoro-benzoyl)-thiazol-2-ylamino]-N-piperidin-4-ylmethyl-benzenesulfonamide, (See Pat. No. 6,569,878, Columns 124 and 193, Example J(4)). These products can be used to alleviate the symptoms of cellular proliferative diseases and cancer (Column 3, lines 29-43).

Ascertainment of the difference between the prior art and the claims (MPEP § 2141.02)

The difference between the `878 Patent and the instantly claimed compounds is a methyl versus hydrogen group. There are two species that are claimed in the instant application that are taught in the `878 Patent. In the first example, the `878 Patent teaches a 4-methyl-piperazine group off the sulfonyl group, while the instant application discloses a piperazine group. The difference being a hydrogen instead of a methyl at the 4 position of the piperazine ring in the instant application. In the second example, the `878 Patent teaches a piperidine group off the sulfonyl group, while the instant application discloses 2-methyl-piperidine. The difference being a methyl instead of a hydrogen at the 2 position of the piperidine ring in the instant application.

Finding of prima facie obviousness – rationale and motivation (MPEP § 2142-2413)

However, in the absence of showing unobvious results, it would have been obvious to one of ordinary skill in the art at the time of the invention when faced with the `878 Patent to make products that are useful for the treatment of cellular proliferative diseases and cancer, wherein methyl and hydrogen are interchangeable.

In the first example noted above, the `878 Patent teaches a tertiary amine and the instant application discloses a secondary amine. This is an obvious variant. The interchange of alkyl and

hydrogen is obvious in and of itself. Secondary and tertiary amines are interchangeable. Ex parte Bluestone, 135 USPQ 199.

In the second example, the `878 Patent teaches a hydrogen substituent off the piperidine ring, while the instant application discloses a methyl substituent. Hydrogen and methyl are deemed obvious variants. In re Wood, 199 USPQ 137.

The motivation would be to prepare similar compounds pharmacologically active against cellular proliferative diseases and cancer. Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention when faced with the `878 Patent to make products that are useful for the treatment of cellular proliferative diseases and cancer, wherein methyl and hydrogen are interchangeable.

Claim Rejections - 35 USC § 112, 2nd paragraph

The following is a quotation of the second paragraph of 35 U.S.C. 112:

> The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 1 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Specifically, Claim 1 is indefinite because the R6 moiety is not defined. Claim 1 discloses that "R6 is a group selected from the following formulae: wherein, etc...." The substituents of R6 are missing therefore the claim is indefinite. The substituents of R6 must be inserted after the word"formulae:" to overcome this rejection.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the

mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susannah Lee whose telephone number is (571) 272-6098. The examiner can normally be reached on M-F, 8am-5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane can be reached on (571) 272-0699. The fax phone number for the organization where this application or proceeding is assigned is (571) 272-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

KAMAL A. SAEED, PH.D.
PRIMARY EXAMINER

Susannah Lee
Patent Examiner, AU 1626

for Joseph K. McKane
Supervisory Patent Examiner
AU 1626
Date: 05/10/05

PTO.SB/08A (04-03)
Approved for use through 04/30/03. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known	
Application Number	10/776,450
Filing Date	February 11, 2004
First Named Inventor	Wesley K. M. Chong
Art Unit	1645
Examiner Name	TBA
Attorney Docket Number	PC19074A

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	Cite No.[1]	DOCUMENT NUMBER Number-Kind Code[2]	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
SL	AA	US 3,810,993	05-14-1974	Basel Dieter Duerr, et al.	
SL	AB	US 6,114,365	09-05-2000	Paolo Pevarello, et al	
SL	AC	US 6,262,096	07-17-2001	Sikim Kyoung, et al	
SL	AD	US 6,569,878	05-27-2003	Wesley K. M. Chong, et al.	
SL	AE	US 6,720,346	04-13-2004	Shao Song Chu, et al.	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
SL	AF	FR 1528249	06-19-1967	Ciba-Geigy AG		
SL	AG	WO 96/14843	05-23-1996	Cor Therapeutics, Inc.		
SL	AH	WO 97/34876	09-22-1997	Zeneca Limited		
SL	AI	EP 816362A	01-07-1998	Taisho Pharmaceutical Co., Ltd.		
SL	AJ	WO 98/04536	02-05-1998	Otsuka Pharmaceutical Company, Limited		
SL	AK	WO 99/21845	05-06-1999	Agouron Pharmaceuticals Inc.		
SL	AL	WO 99/24035	05-20-1999	Bristol-Myers Squibb Co.		
SL	AM	WO 99/62890	12-09-1999	Pfizer Products, Inc.		

EXAMINER: Susannah Lee	DATE CONSIDERED: 5/10/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kindof document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

PTO.SB/08A (04-03)
Approved for use through 04/30/03. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. Department of Commerce
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known	
Application Number	10/776,450
Filing Date	February 11, 2004
First Named Inventor	Wesley K. M. Chong
Art Unit	1645
Examiner Name	TBA
Attorney Docket Number	PC19074A

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
SL	AN	WO 00/17175	03-30-2000	Vertex Pharmaceuticals Incorporated		
SL	AO	WO 00/26202	05-11-2000	Pharmacia & Upjohn S.P.A.		
SL	AP	WO 00/26203	05-11-2000	Pharmacia & Upjohn S.P.A.		
SL	AQ	WO 00/75120	12-14-2000	Agouron Pharmaceuticals Inc.		
SL	AR	WO 01/144241	06-21-2001	Bristol-Myers Squibb Co.		
SL	AS	WO 01/44242	06-21-2001	Bristol-Myers Squibb Co.		
SL	AT	WO 02/57261	07-25-2002	F. Hoffmann-La Roche AG		
SL	AU	WO 03/04467	01-16-2003	Agouron Pharmaceuticals, Inc.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
SL	AV	AKAMA, T., et al., "Synthesis Of An Ethyl 6-Amino-3,5-Difluorosalicylate Derivative By Sequential Regioselective Directed *Ortho*-Metalation: A Practical Synthesis of 4',5-Diamino-3',6,8-Trifluoroflavone, A Potent Antitumor Agent," *Synthesis*, 1997, 1446-1450.	
SL	AW	BAER, R., et al., "A Novel Solid-Phase Approach To 2,4-Diaminothiazoles," *J. Comb. Chem.*, 2001, 16-19, vol. 3.	
SL	AX	BAGSHAWE, K., "Antibody-Directed Enzyme Prodrug Therapy: A Review," *Drug Development Research*, 1995, 220-230, vol. 34.	
SL	AY	BENNETAU, B., et al., "Fonctionnalisation Regioselective En Position 2 De Benzenes 1,3-Disubstitues," *Tetrahedron*, 1993, 10843-10854, vol. 49, no. 47.	

EXAMINER: Susannah Lee	DATE CONSIDERED: 5/10/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use as many sheets as necessary)

Complete if Known	
Application Number	10/776,450
Filing Date	February 11, 2004
First Named Inventor	Wesley K. M. Chong
Art Unit	1645
Examiner Name	TBA
Attorney Docket Number	PC19074A

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
SL	AZ	BERTOLINI, G., et al., "A New Rational Hypothesis For The Pharmacophore Of The Active Metabolite Of Leflunomide, A Potent Immunosuppressive Drug," *J. Med. Chem.*, 1997, 2011-2016, vol. 40.	
SL	BA	BINU, R. et al., "Synthesis And Cyclization Of 1-(N-Nitroamidino) Thioureas To 2,4-Diaminothiazoles," *Org. Prep. Proced. Intl.*, 1998, 93-96, vol. 30, no. 1.	
SL	BB	BODOR, N., "Novel Approaches To The Design Of Safer Drugs: Soft Drugs And Site-Specific Chemical Delivery Systems," *Advances in Drug Research*, 1984, 254-331, vol. 13.	
SL	BC	BORGEN, R., et al., "Proton Magnetic Resonance Spectra Of Thiazoles," *Acata. Chemica Scandinavica*, 1966, 2593-2600, vol. 20.	
SL	BD	BUOLAMWINI, J., "Cell Cycle Molecular Targets In Novel Anticancer Drug Discovery," *Current Pharmaceutical Design*, 2000, 379-392, vol. 6.	
SL	BE	CHEMICAL ABSTRACTS, 1969, CIBA Ltd., vol. 71, 263, 30206e.	
SL	BF	CHEN, G., et al., "Syntheses Of 2,5- and 2,6-Difluoronorepinephrine, 2,5-Difluoroepinephrine, And 2,6-Difluorophenylephrine: Effect Of Disubstitution With Fluorine On Adrenergic Activity," *J. Med. Chem.*, 1993, 3947-3955, vol. 36.	
SL	BG	CHUCHANI, G., et al., "Tritylation Of Aminobenzenethiois," *J. Chem. Soc. C*, 1969, 1436-1437.	
SL	BH	CREWS, C., et al., "Small-Molecule Inhibitors Of The Cell Cycle," *Current Opinion in Chemical Biology*, 2000, 47-53, vol. 4.	
SL	BI	DEAR, G., et al., "Mass Directed Peak Selection, An Efficient Method Of Drug Metabolite Identification Using Directly Coupled Liquid Chromatography-Mass Spectrometry-Nuclear Magnetic Resonance Spectroscopy," *Journal of Chromatography* B., 2000, 281-293, vol. 748.	
SL	BJ	DEVI, S., et al., "Synthesis Of 2,4-Diamino-5-(FUR-2-OYL), (THIEN-2-OYL), And (PYRID-2-OYL) Thiazoles," *Synthetic Communications*, 2002, 1523-1528, vol. 32, no. 10.	
SL	BK	GEWALD, V., et al., "4-Amino-Thiazole," *J. Pract. Chem.*, 1967, 97-104, vol. 35.	

EXAMINER: Susannah Lee	DATE CONSIDERED: 5/10/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use as many sheets as necessary)

Complete if Known	
Application Number	10/776,450
Filing Date	February 11, 2004
First Named Inventor	Wesley K. M. Chong
Art Unit	1645
Examiner Name	TBA
Attorney Docket Number	PC19074A

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
SL	BL	GRAY, N., et al., "ATP-Site Directed Inhibitors Of Cyclin-Dependent Kinases," *Current Medicinal Chemistry*, 1999, 859-875, vol. 6.	
SL	BM	HERNANDEZ, A., et al., "Solid-Supported *Tert*-Alkoxycarbonylation Reagents For Anchoring Of Amines During Solid Phase Organic Synthesis," *J. Org. Chem.*, 1997, 3153-3157, vol. 62.	
SL	BN	HOSOI, T., et al., "Evidence For cdk5 As A Major Activity Phosphorylating Tau Protein In Porcine Brain Extract," *J. Biochem.*, 1995, 741-749, vol. 117.	
SL	BO	JEFFREY, P., et al., "Mechanism Of CDK Activation Revealed By The Structure Of A cyclinA-CDK2 Complex," *Nature*, 1995, 313-320, vol. 376.	
SL	BP	JENARDANAN, G., et al., "1-(N-Arylthiocarbamoyl) Amidino-3,5-Dimethyl Pyrazoles-Preparation And Use In Heterocycle Synthesis," *Synthetic Communications*, 1997, 3457-3462, vol, 27, no. 19.	
SL	BQ	JONES, T., et al., "Structure-Based Design Of Lipophilic Quinazoline Inhibitors Of Thymidylate Synthase," *J. Med. Chem*, 1996, 904-917, vol. 39.	
SL	BR	JOSHI, K., et al., "Studies In Fluorinated 1,3-Diketones And Related Compounds Part XIII: Synthetic And Spectral Studies Of Some New Fluorinated *Tris* Europium 1,3-Diketonates," *J. Indian, Chem. Soc.*, 1982, 293-294, vol. 59.	
SL	BS	KIMBALL, S., et al., "Cell Cycle Kinases And Checkpoint Regulation In Cancer," *Ann. Rep. Med. Chem.*, 2001, 139-148, vol. 36.	
SL	BT	KING, C., et al., "Selective Bromination With Copper (II) Bromide," *J. Org. Chem.*, 1964, 3459-3461, vol. 29.	
SL	BU	KRAZER, B., *et al.*, "The Nature Of The Bond Between reactive Dyes And Cellulose," *Helvetica Chimica Act.*, 1960, 1513-1519, vol. 43.	
SL	BV	KUO, Y., et al., "A New Method For Preparation Of 3-Hydroxypyridines From Furfurylamines By Photooxygenation," *Chem. Pharm. Bull.*, 1991, 181-183, vol. 39, no. 1.	
SL	BW	LEE, R., et al., "New Synthetic Cluster Ligands For Galactose/*N*-Acetylgalactosamine-Specific Lectin Of Mammalian Liver," *Biochemistry*, 1984, 4255-4261, vol. 23.	

EXAMINER: Susannah Lee	DATE CONSIDERED: 5/10/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use as many sheets as necessary)

Complete if Known	
Application Number	10/776,450
Filing Date	February 11, 2004
First Named Inventor	Wesley K. M. Chong
Art Unit	1645
Examiner Name	TBA
Attorney Docket Number	PC19074A

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
SL	BX	MASQUELIN, T., et al., "A New General Three Component Solution-Phase Synthesis Of 2-Amino-1,3-Thiazole And 2,4-Diamino-1,3-Thiazole Combinatorial Libraries," *Tetrahedron*, 2001, 153-156, vol. 57.	
SL	BY	MC KEE, R., et al., "p-Substituted Phenyl Isothiocyanates And Some Related Thioureas," *J. Am. Chem. Soc.*, 1946, 2506-2507, vol. 68.	
SL	BZ	MC MORRIS, T., et al., "Improved Synthesis Of Brassinolide," *J. Chem. Soc. Perkin Trans. 1*, 1996, 295-302.	
SL	CA	MEIJER, L., et al., "Chemical Inhibitors Of Cyclin-Dependent Kinases," *Methods in Enzymology*, 1997, 113-128, vol. 283.	
SL	CB	METZGER, J., et al., "Organometallic Derivatives of Thiazole. II. Organolithium Derivs," *Bulletin de la Societe Chimique de France*, 1953, 708-709.	
SL	CC	MLOTKOWSKA, B., et al., "Reactions Of 2,4- And 2,6-Dichlorophenacylidene Halides With Trialkylphosphites In Protic Solvents. Direct Evidence For The "Enolate Anion" Pathway," Polish Journal of Chemistry, 1981, 631-642, vol. 55.	
SL	CD	MOSMANN, T., et al., "Rapid Colorimetric Assay For Cellular Growth And Survival: Application To Proliferation And Cytotoxicity Assays," *Journal of Immunological Methods*, 1983, 55-63, vol. 65.	
SL	CE	PARAST, C., et al., "Characterization And Kinetic Mechanism Of Catalytic Domain Of Human Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase (VEGFR2 TK), A Key Enzyme In Angiogenesis," *Biochemistry*, 1998, 16788-16801, vol. 37.	
SL	CF	PIEPER, H., et al., "Preparation And Biological Activity Of New Substituted Antimalarial Diaminodiphenylsulfones," *Arzneim. Forsch.*, 1989, 1073-1080, vol. 39, no. II.	
SL	CG	PROX., A., et al., "Rapid Structure Elucidation Of Drug Metabolites By Use Of Stable Isotopes," *Xenobiotica*, 1973, 103-112, vol. 3, no. 2.	
SL	CH	RAJASEKHARAN, K., et al., "Studies On The Synthesis Of 5-Acyl-2,4-Diaminothiazoles From Amidinothioureas," *Synthesis*, 1986, 353-355.	
SL	CI	ROSANIA, G., et al., "Targeting Hyperproliferation Disorders With Cyclin Dependent Kinase Inhibitors," *Expert Opinion On Therapeutic Patents*, 2000, 215-230, vol. 10, no. 2.	

EXAMINER: Susannah Lee	DATE CONSIDERED: 5/10/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

PTO.SB/08A (04-03)
Approved for use through 04/30/03. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use as many sheets as necessary)

Complete if Known	
Application Number	10/776,450
Filing Date	February 11, 2004
First Named Inventor	Wesley K. M. Chong
Art Unit	1645
Examiner Name	TBA
Attorney Docket Number	PC19074A

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
SL.	CJ	ROSENBLATT, J., et al., "Purification And Crystallization Of Human Cyclin-Dependent Kinase 2," *J. Mol. Biol.*, 1993, 1317-1319, vol. 230.	
SL	CK	SCHANG, L., et al., "Roscovitine, A Specific Inhibitor Of Cellular Cyclin-Dependent Kinases, Inhibits Herpes Simplex Virus DNA Synthesis In The Presence Of Viral Early Proteins," *Journal Of Virology*, 2000, 2107-2120, vol. 74, no. 5.	
SL	CL	SHAN, D., et al., "Prodrug Strategies Based On Intramolecular Cyclization Reactions," *Journal Of Pharmaceutical Sciences*, 1997, 765-767, vol. 86, no 7.	
SL	CM	SIELECKI, T., et al., "Cyclin-Depedent Kinase Inhibitors: Useful Targets In Cell Cycle Regulation," *Journal of Medicinal Chemistry*, 2000, 1-18, vol. 43, no. 1.	
SL	CN	SPRAUL, M., et al., "Liquid Chromatography Coupled With High-Field Proton NMR For Profiling Human Urine For Endogenous Compounds And Drug Metabolites," *Journal of Pharmaceutical and Biomedical Analysis*, 1992, 601-605, vol. 10, no. 8.	
SL	CO	STILL, W., et al., "Rapid Chromatographic Technique For Preparative Separations With Moderate Resolution," J. Org. Chem., 1978, 2923-2925, vol. 43, no. 14.	
SL	CP	STOVER, D., et al., "Recent Advances In Protein Kinase Inhibition: Current Molecular Scaffolds Used For Inhibitor Synthesis," *Current Opinion In Drug Discovery*, 1999, 274-285, vol. 2, no. 4.	
SL	CQ	TAKAHASHI, T., et al., "Syntheses Of Heterocyclic Compounds Of Nitrogen LXXXVIII," *Pharm. Bull.*, 1954, 30-34, vol. 2, no. 1.	
SL	CR	TOOGOOD, P., et al., "Cyclin-Dependent Kinase Inhibitors For Treating Cancer," *Medicinal Research Reviews*, 2001, 487-498, vol. 21, no. 6.	
SL	CS	TOPLISS, J., et al., "Antihypertensive Agents. I. Non-Diuretic 2H-1,2,4-Benzothiadiazine 1,1-Dioxides," *J. Med. Chem.*, 1963, 122-127, vol. 6.	
SL	CT	UHER, M., et al., Chemicke Zvesti, 21, 44-56, Chem. Abs. 43495, 1967	
SL	CU	WEBSTER, K., et al., "The Therapeutic Potential Of Targeting The Cell Cycle," *Expert Opinion On Investigational Drugs*, 1998, 865-887, vol. 7 no. 6.	

EXAMINER: Susannah Lee	DATE CONSIDERED: 5/10/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use as many sheets as necessary)

Complete if Known	
Application Number	10/776,450
Filing Date	February 11, 2004
First Named Inventor	Wesley K. M. Chong
Art Unit	1645
Examiner Name	TBA
Attorney Docket Number	PC19074A

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
SL	CV	YANO, Y., et al., "Stimulatory Effects Of Lipoprotein(a) And Low-density Lipoprotein On Human Umbilical Vein Endothelial Cell Migration And Proliferation Are Partially Mediated By Fibroblast Growth Factor-2," Biochimica et Biophysica Acta, 1998, 26-34, vol. 1393.	

EXAMINER: Susannah Lee	DATE CONSIDERED: 5/10/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Notice of References Cited	Application/Control No. 10/776,450	Applicant(s)/Patent Under Reexamination CHONG ET AL.	
	Examiner Susannah Lee	Art Unit 1626	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-6,569,878	05-2003	Chong et al.	514/370
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Organization TC1600 Bldg./Room REMSEN
U. S. DEPARTMENT OF COMMERCE
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450
IF UNDELIVERABLE RETURN IN TEN DAYS

OFFICIAL BUSINESS

U.S. OFFICIAL MAIL
PENALTY FOR
PRIVATE USE $300
PITNEY BOWES
02 1A
0004204055
$ 01.29⁰
MAY 16 2005
MAILED FROM ZIP CODE 22314

AN EQUAL OPPORTUNITY EMPLOYER

RETURNED TO SENDER
UNDELIVERABLE AS ADDRESSED
INSUFFICIENT ADDRESS
ATTEMPTED NOT KNOWN
NO SUCH NUMBER
OTHER
ROUTE
INITIAL

RECEIVED
MAY 23 2005
USPTO MAIL CENTER

BEST AVAILABLE COPY